JP2023513735A5 - - Google Patents

Info

Publication number
JP2023513735A5
JP2023513735A5 JP2022548856A JP2022548856A JP2023513735A5 JP 2023513735 A5 JP2023513735 A5 JP 2023513735A5 JP 2022548856 A JP2022548856 A JP 2022548856A JP 2022548856 A JP2022548856 A JP 2022548856A JP 2023513735 A5 JP2023513735 A5 JP 2023513735A5
Authority
JP
Japan
Prior art keywords
cancer
ptx3
pentraxin
hyaluronan
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513735A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017773 external-priority patent/WO2021163419A1/en
Publication of JP2023513735A publication Critical patent/JP2023513735A/ja
Publication of JP2023513735A5 publication Critical patent/JP2023513735A5/ja
Pending legal-status Critical Current

Links

JP2022548856A 2020-02-12 2021-02-12 がん細胞を死滅させるまたはがん細胞の成長を阻害する方法 Pending JP2023513735A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062975599P 2020-02-12 2020-02-12
US62/975,599 2020-02-12
PCT/US2021/017773 WO2021163419A1 (en) 2020-02-12 2021-02-12 Methods of killing or inhibiting the growth of cancer cells

Publications (2)

Publication Number Publication Date
JP2023513735A JP2023513735A (ja) 2023-04-03
JP2023513735A5 true JP2023513735A5 (enExample) 2024-02-21

Family

ID=77292678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548856A Pending JP2023513735A (ja) 2020-02-12 2021-02-12 がん細胞を死滅させるまたはがん細胞の成長を阻害する方法

Country Status (8)

Country Link
US (1) US20230083005A1 (enExample)
EP (1) EP4103592A4 (enExample)
JP (1) JP2023513735A (enExample)
KR (1) KR20220143689A (enExample)
CN (1) CN115397841A (enExample)
AU (1) AU2021219772A1 (enExample)
CA (1) CA3170323A1 (enExample)
WO (1) WO2021163419A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
WO2023211823A1 (en) 2022-04-25 2023-11-02 Biotissue Holdings Inc. Compositions and methods relating to pooled fetal support tissue

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
SE8200751L (sv) 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
US5037677A (en) 1984-08-23 1991-08-06 Gregory Halpern Method of interlaminar grafting of coatings
US5356433A (en) 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US5336518A (en) 1992-12-11 1994-08-09 Cordis Corporation Treatment of metallic surfaces using radiofrequency plasma deposition and chemical attachment of bioactive agents
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
EP1691820A4 (en) * 2003-11-08 2010-03-03 Prothera Biolog PREPARATION AND COMPOSITION OF INTER ALPHA HEMMER PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE
CA2999420A1 (en) * 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8093365B2 (en) 2008-03-03 2012-01-10 New York University Biocompatible materials containing stable complexes method of TSG-6 and hyaluronan and method of using same
EP3838293A1 (en) * 2012-07-11 2021-06-23 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
TWI720984B (zh) * 2015-05-20 2021-03-11 美商帝聖工業公司 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
EP3876963A4 (en) * 2018-11-07 2022-08-17 Tissuetech, Inc. PROCEDURE FOR CELL REPROGRAMMING

Similar Documents

Publication Publication Date Title
Wang et al. Combination of ablation and immunotherapy for hepatocellular carcinoma: where we are and where to go
Power et al. Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors–An update
Zhang et al. Advancements of radiotherapy for recurrent head and neck cancer in modern era
Martin II et al. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma
US20220280233A1 (en) Devices, methods, and compositions for thermal acceleration and drug delivery
US20190216899A1 (en) Systems and methods for cardiac plexus neuromodulation
Araujo et al. Radiation-induced damage in the lower gastrointestinal tract: Clinical presentation, diagnostic tests and treatment options
JP2022500435A5 (enExample)
Rogers et al. Radiotherapy for melanoma: More than DNA damage
CN109069624A (zh) 癌症的免疫治疗
Szasz Current status of oncothermia therapy for lung cancer
JP2019530673A5 (enExample)
Zhou et al. A comprehensive review of BET-targeting PROTACs for cancer therapy
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
JP2023513735A5 (enExample)
CN104800858B (zh) Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
Timmer et al. Locally advanced pancreatic cancer: percutaneous management using ablation, brachytherapy, intra-arterial chemotherapy, and intra-tumoral immunotherapy
Zhou et al. New advances in treatment of skin malignant tumors with nanosecond pulsed electric field: A literature review
Zhao et al. Synergistically Augmenting Cancer Immunotherapy by Physical Manipulation of Pyroptosis Induction: C. Zhao et al.
Metcalfe et al. The safety and efficacy of radiofrequency and electrolytic ablation created adjacent to large hepatic veins in a porcine model
Tian et al. Visualized photodynamic nanomaterials activating tumor-associated immune landscape as a next-generation anticancer strategy
WO2009067520A3 (en) Peptides specific for hepatocellular carcinoma cells and applications thereof
Nunez-Mora et al. Radical laparoscopic salvage prostatectomy: medium-term functional and oncological results
Lauffer et al. Pancreatic cancer: feasibility and outcome after radiochemotherapy with high dose external radiotherapy for non-resected and R1 resected patients
Sbeit et al. Endoscopic ultrasound role in pancreatic adenocarcinoma treatment: A review focusing on technical success, safety and efficacy